Can a higher dose of xolair beat food allergies?
NCT ID NCT06943534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if higher doses of omalizumab (Xolair) can help people with food allergies tolerate more of their trigger foods. Thirty participants with allergies to peanut, cashew, walnut, egg, or milk will receive either 5 mg/kg or 15 mg/kg of omalizumab for 16 weeks. The goal is to see if they can then eat at least 600 mg of the allergen without a reaction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
omalizumab (Xolair)
What this could lead to
If successful, this could lead to a more effective dosing strategy for omalizumab, helping people with food allergies tolerate larger amounts of trigger foods without severe reactions.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Higher doses may also increase side effects or fail to improve tolerance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••